JPWO2020207991A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020207991A5
JPWO2020207991A5 JP2021559754A JP2021559754A JPWO2020207991A5 JP WO2020207991 A5 JPWO2020207991 A5 JP WO2020207991A5 JP 2021559754 A JP2021559754 A JP 2021559754A JP 2021559754 A JP2021559754 A JP 2021559754A JP WO2020207991 A5 JPWO2020207991 A5 JP WO2020207991A5
Authority
JP
Japan
Prior art keywords
methyl
hexahydro
pyrazino
amino
carbonitrile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021559754A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527588A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/059831 external-priority patent/WO2020207991A1/en
Publication of JP2022527588A publication Critical patent/JP2022527588A/ja
Publication of JPWO2020207991A5 publication Critical patent/JPWO2020207991A5/ja
Pending legal-status Critical Current

Links

JP2021559754A 2019-04-09 2020-04-07 自己免疫疾患の治療のためのヘキサヒドロ-1H-ピラジノ[1,2-a]ピラジン化合物 Pending JP2022527588A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/081900 2019-04-09
CN2019081900 2019-04-09
CNPCT/CN2019/121598 2019-11-28
CN2019121598 2019-11-28
CN2020078225 2020-03-06
CNPCT/CN2020/078225 2020-03-06
PCT/EP2020/059831 WO2020207991A1 (en) 2019-04-09 2020-04-07 Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease

Publications (2)

Publication Number Publication Date
JP2022527588A JP2022527588A (ja) 2022-06-02
JPWO2020207991A5 true JPWO2020207991A5 (zh) 2023-04-10

Family

ID=70228042

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021559754A Pending JP2022527588A (ja) 2019-04-09 2020-04-07 自己免疫疾患の治療のためのヘキサヒドロ-1H-ピラジノ[1,2-a]ピラジン化合物

Country Status (18)

Country Link
US (1) US20220340597A1 (zh)
EP (1) EP3953356B1 (zh)
JP (1) JP2022527588A (zh)
KR (1) KR20210149163A (zh)
CN (1) CN113710672A (zh)
AU (1) AU2020272467A1 (zh)
BR (1) BR112021020297A2 (zh)
CA (1) CA3135129A1 (zh)
CL (1) CL2021002621A1 (zh)
CO (1) CO2021013166A2 (zh)
CR (1) CR20210513A (zh)
IL (1) IL286870A (zh)
MA (1) MA55594A (zh)
MX (1) MX2021012223A (zh)
PE (1) PE20212178A1 (zh)
SG (1) SG11202110401WA (zh)
TW (1) TW202104230A (zh)
WO (1) WO2020207991A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114599652B (zh) * 2019-10-31 2024-07-12 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的氢吡嗪并[1,2-d][1,4]二氮杂䓬化合物
US20230002375A1 (en) * 2019-11-12 2023-01-05 Hoffmann-La Roche Inc. Hydropyrazino[1,2-b]isoquinoline compounds for the treatment of autoimmune disease
PE20231098A1 (es) 2019-11-28 2023-07-18 Bayer Ag Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activacion inmune
EP4069693B1 (en) * 2019-12-03 2024-03-20 F. Hoffmann-La Roche AG Hydropyrido[1,2-alpha]pyrazine compounds for the treatment of autoimmune diseases
WO2022013136A1 (en) * 2020-07-14 2022-01-20 F. Hoffmann-La Roche Ag Hydroisoquinoline or hydronaphthyridine compounds for the treatment of autoimmune disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2663555T (pt) * 2011-01-12 2017-03-23 Array Biopharma Inc Benzoazepinas substituídas como moduladores de recetores tipo-toll
PE20150735A1 (es) 2012-09-14 2015-05-17 Hoffmann La Roche Derivados de pirazol-carboxamida como moduladores de taar para uso en el tratamiento de numerosos desordenes, tales como depresion, diabetes y enfermedad de parkinson
CA2933466A1 (en) * 2013-12-13 2015-06-18 Takeda Pharmaceutical Company Limited Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors
SI3889145T1 (sl) * 2015-12-17 2024-05-31 Merck Patent Gmbh 8-ciano-5-piperidino-kinolini kot antagonisti tlr7/8 in njihove uporabe za zdravljenje imunskih motenj
EP3807271A1 (en) * 2018-06-13 2021-04-21 F. Hoffmann-La Roche AG Pyridinyl heterocyclyl compounds for the treatment of autoimmune disease
WO2020064792A1 (en) * 2018-09-27 2020-04-02 F. Hoffmann-La Roche Ag Heterocyclyl compounds for the treatment of autoimmune disease

Similar Documents

Publication Publication Date Title
US11591336B2 (en) Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors
HRP20180080T1 (hr) Pirimidopirimidinoni korisni kao inhibitori wee-1 kinaze
JP2019535664A5 (zh)
RU2019115115A (ru) Производные пиперидина в качестве ингибиторов убиквитин-специфической протеазы 7
JP5911638B2 (ja) ベンゾチアゾール−6−イル酢酸誘導体およびhiv感染を処置するためのそれらの使用
TWI805629B (zh) 用於治療發炎性病症之新穎化合物及其醫藥組合物
JPWO2020081848A5 (zh)
CN105294683A (zh) Cdk类小分子抑制剂的化合物及其用途
CN105294681A (zh) Cdk类小分子抑制剂的化合物及其用途
TW201219398A (en) Furo[3,2-d]pyrimidine compounds
JPWO2019191092A5 (zh)
JP2020510092A5 (zh)
AU2022265682A1 (en) 2-aminobenzothiazole compounds and methods of use thereof
TW202321242A (zh) 雜環化合物及使用方法
JP2021526535A (ja) 自己免疫疾患の処置のための新規のヘテロアリールヘテロシクリル化合物
AU2021370660A1 (en) Heterocyclic spiro compounds and methods of use
JP7511097B1 (ja) Her2変異阻害薬
US20200079763A1 (en) Quinoxaline and pyridopyrazine derivatives as a pi3kb inhibitors
RU2012131115A (ru) Ингибиторы активности акт
JP2021506885A (ja) マルチキナーゼ阻害剤としてのカルバメートおよび尿素化合物
JPWO2020207991A5 (zh)
JP2018537508A (ja) キナーゼ阻害剤としての三環式化合物および組成物
JPWO2019233941A5 (zh)
JPWO2019197842A5 (zh)
JP2016537384A5 (zh)